Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 17.09% is 10% above its 5-year average of 15.48%, around the middle of its 5-year range (5.73%–23.64%).
As of the fiscal period ended Tuesday, June 30, 2026. 14.91% below its 12-month average of 20.08%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 17.09%.
DEBT TO ASSETS RATIO
17.09%
DEBT TO ASSETS RATIO AVG TTM
20.08%
DEBT TO ASSETS RATIO AVG 3Y
18.32%
DEBT TO ASSETS RATIO AVG 5Y
15.48%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-14.91%
CURRENT VS 3Y AVG
-6.72%
CURRENT VS 5Y AVG
+10.40%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+18886.80%
vs the sector median at left
Sana Biotechnology, Inc.
Market Cap
$783.39M
Debt to Assets Ratio
17.09%
TTM Avg
20.08%
3Y Avg
18.32%
5Y Avg
15.48%
Market Cap
$778.22M
Debt to Assets Ratio
0.34%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$775.12M
Debt to Assets Ratio
0.24%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$794.92M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$765.90M
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$804.96M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | $783.39M | 17.09% | 20.08% | 18.32% | 15.48% |
| Geron Corporation (GERN)vs › | $782.66M | 0.24% | N/A | N/A | N/A |
| Varex Imaging Corporation (VREX)vs › | $778.22M | 0.34% | N/A | N/A | N/A |
| AdaptHealth Corp. (AHCO)vs › | $787.81M | 0.48% | N/A | N/A | N/A |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $775.12M | 0.24% | N/A | N/A | N/A |
| Gyre Therapeutics, Inc. (GYRE)vs › | $794.92M | 0.02% | N/A | N/A | N/A |
| Attovia Therapeutics, Inc. (ATTO)vs › | $765.90M | 0.03% | N/A | N/A | N/A |
| InMode Ltd. (INMD)vs › | $802.43M | 0.01% | N/A | N/A | N/A |
| Jade Biosciences, Inc. (JBIO)vs › | $804.96M | 0.00% | N/A | N/A | N/A |
| Mesa Laboratories, Inc. (MLAB)vs › | $759.16M | 0.24% | N/A | N/A | N/A |
Debt/Assets
17.1%
Debt/Equity
0.48
Current Ratio
1.38
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 17.09% |
| 2026-03-31 | 20.16% |
| 2025-12-31 | 18.92% |
| 2025-09-30 | 20.61% |
| 2025-06-30 | 23.64% |
| 2025-03-31 | 20.50% |
| 2024-12-31 | 18.80% |
| 2024-09-30 | 17.18% |
| 2024-06-30 | 15.93% |
| 2024-03-31 | 15.57% |
| 2023-12-31 | 18.41% |
| 2023-09-30 | 15.34% |
| 2023-06-30 | 16.00% |
| 2023-03-31 | 15.33% |
| 2022-12-31 | 13.16% |
| 2022-09-30 | 12.45% |
| 2022-06-30 | 11.70% |
| 2022-03-31 | 10.71% |
| 2021-12-31 | 9.82% |
| 2021-09-30 | 8.02% |
| 2021-06-30 | 5.73% |
| 2021-03-31 | 5.39% |
| 2020-12-31 | 9.85% |
| 2020-09-30 | 9.20% |
| 2019-12-31 | 11.49% |
